Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression

American Journal of Pathology

Volumn 162, Issue 4, 2003, Pages 1139-1149

  Chopin, Dominique ^a   Barei Moniri, Reza ^a   Maillé, Pascale ^a   Le Frère Belda, Marie Aude ^a   Muscatelli Groux, Béatrice ^a   Merendino, Nicolò ^b   Lecerf, Laure ^a   Stoppacciaro, Antonella ^c   Velotti, Francesca ^a,c  

^a HENRI MONDOR HOSPITAL   (France)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF TUSCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CD8 ANTIGEN; FAS LIGAND; GAMMA INTERFERON;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CELL KILLING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIXED LYMPHOCYTE CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; UROTHELIUM;

EID: 0037378554     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63910-7     Document Type: Article

References (35)

1. Hudson MA, Catalona WJ: Urothelial tumors of the bladder, upper tracts and prostate. Adult and Pediatric Urology. Edited by JY Gillenwater, JT Grayhack, SS Howards, JW Duckett. St. Louis, Mosby, 1996, pp 643-694
2. Velotti F, Chopin D, Gil-Diez S, Maillé P, Abbou CC, Kourilsky P, Even J: Clonality of tumor-infiltrating lymphocytes in human urinary bladder carcinoma. Immunotherapy 1997, 20:470-478
3. Herr HW, Schwalb DM, Zhang Z-F, Sogani PC, Fair WR, Whitmore Jr WF, Oettgen HF: Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995, 13:1404-1408
4. Velotti F, Cippitelli M, Giuffrida AM, Punturieri A, Moretti F, Stoppacciaro A, Tubaro A, De Maria R, Santoni A: Local immunotherapy of human bladder cancer with recombinant IL-2. Cytokine-Induced Tumor Immunogenicity. Edited by G Forni, R Foa, A Santoni, L Frati. New York, Academic Press, 1994, pp 429-442
5. Patard J-J, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, François P, Abi-Aad A, Van Caugh P, Abbou CC, Chopin D, Boon T: Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 1995, 64:60-64
6. Tureci O, Chen Y-T, Sahin U, Gure AO, Zwick C, Villena C, Tsang S, Seitz G, Old LJ, Pfreundschuh M: Expression of SSX genes in human tumors. Int J Cancer 1998, 77:19-23
7. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and significance. Adv Immunol 2000, 74:181-273
8. Nagata S, Golstein P: The Fas death factor. Science 1995, 267:1449-1456
9. Barry M, Bleakley RC: Cytotoxic T lymphocytes: all roads lead to death. Nature 2002, 2:401-409
10. Grifith ST, Fergusson TA: The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997, 18:240-244
11. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996, 184:1075-1082
12. Hahne M, Rimoldi D, Schröter M, Romer P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J: Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366
13. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasions? Nat Med 1996, 2:1361-1366
14. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999, 1:46-53
15. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F: Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 2001, 7:271-274
16. Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, Wagner G: Urinary bladder. TNM Atlas, Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors. Edited by Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, Wagner G, International Union Against Cancer (Union International Contre le Cancer; UICC). Berlin, Springer-Verlag, 1992, pp 214-279
17. Mostofi FK, Sobin LH, Torloni H: Histological typing of urinary bladder tumors. International Histological Classification of Tumors. Edited by World Health Organization. Geneva, World Health Organization, 1973, pp 400-415
18. De Boer WI, Houtsmuller AB, Izadifar V, Muscatelli-Groux B, van der Kwast T, Chopin DK: Expression and functions of EGF, FGF, and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. Int J Cancer 1997, 71: 284-291
19. Herin M, Lemoine C, Weynants P, Vessiere F, Van Pel A, Knuth A, Devos R, Boon T: Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 1987, 39:390-396
20. Smith D, Sieg S, Kaplan D: Technical note: aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J Immunol 1998, 160:4159-4160
21. Asselin-Paturel C, Pardoux C, Gay F, Chouaib S: Failure of TGFbetal and IL-12 to regulate human FasL and mTNF alloreactive cytotoxic T-cell pathways. Tissue Antigens 1998, 51:242-249
22. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63
23. Gown AM, Willingham MC: Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 2002, 50:449-454
24. Perabo FGE, Kamp S, Schmidt D, Lindner H, Steiner G, Mattes RH, Wirger A, Pegelow K, Albers P, Kohn EC, von Ruecker A, Mueller SC: Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br J Cancer 2001, 84:1330-1338
25. Lee SH, Lee JY, Park WS, Kim SY, Jang JJ, Yoo NJ: Transitional cell carcinoma expresses high levels of fas ligand in vivo. BJU Int 1999, 83:698-702
26. Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T: Significance of soluble Fas ligand in patients with bladder carcinoma. Cancer 2001, 92:287-293
27. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL: Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. J Clin Invest 1998, 11:2579-2588
28. Walker PR, Saas P, Dietrich P-Y: Role of Fas ligand (CD95L) in immune escape. J Immunol 1997, 158:4521-4524
29. Lenardo MJ: The molecular regulation of lymphocyte apoptosis Semin Immunol 1997, 9:1-5
30. Guéguen, M, Patard J-J, Gaugler B, Brasseur F, Renauld J-C, Van Cangh PJ, Boon T, Van den Eynde BJ: An antigen recognized by autologous CTL on a human bladder carcinoma. J Immunol 1998, 160:6188-6194
31. Heidecker L, Brasseur F, Probst-Kepper M, Guégen M, Boon T, Van den Eynde BJ: Cytolytic T lymphocytes raised against human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J Immunol 2000, 164:6041-6045
32. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankestein T, Dörken B: Costimulatory signals through B7.1/C28 prevent T cell apoptosis during target cell lysis. J Immunol 1997, 159:3808-3815
33. Herr W, Schneider J, Lohse AW, Meyer zum Buschenfelde KH, Wolfel T: Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1966, 191:131-142
34. Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, Naeher H, Rammensee HG, Keilholz U: Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer 1997, 71:932-936
35. Asemissen AM, Nagorsen D, Keilholz U, Letsch A, Schmittel A, Thiel E, Scheibenbogen C: Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. J Immunol Methods 2001, 251:101-108